HighTower Advisors
SMMT icon

HighTower Advisors’s Summit Therapeutics SMMT Stock Holding History

HighTower Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,200
Closed -$1.03K – 4032
2024
Q3 		$1.03K Buy
+1,200
New +$16.8K ﹤0.01% 3664

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCMH
Polymer Capital Management (HK) Hong Kong $1.16B AUM 135.84% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

HighTower Advisors's SMMT Position: Q4 2025 in Review

HighTower Advisors sold out of Summit Therapeutics (SMMT) in Q4 2025, closing a stake of 10,758 shares — an estimated $222K sold.

HighTower Advisors first reported a position in SMMT in Q4 2023 and held it in 8 quarters. The position peaked at $857K in Q3 2024. 206 funds tracked by Wall St. Rank hold SMMT as of Q4 2025.

  • HighTower Advisors reported no remaining Summit Therapeutics position as of Q4 2025 after selling out during the quarter.
  • HighTower Advisors sold 10,758 Summit Therapeutics shares in Q4 2025, an estimated $222K.
  • HighTower Advisors first reported a position in Summit Therapeutics in Q4 2023 and held it in 8 quarters.
  • HighTower Advisors's Summit Therapeutics position peaked at $857K in Q3 2024.
  • 206 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2025.

Based on HighTower Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.